Clinical Trial Update: REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels [Phase 3]

View source ↗

Summary

This document provides an update on the Phase 3 clinical trial REDEFINE 3 evaluating CagriSema in people with cardiovascular disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease

Drugs mentioned

• CagriSema (cagrilintide/semaglutide)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Cardiovascular Disease | Phase 3 | Status: ACTIVE_NOT_RECRUITING